LACTOLOGY FOUNDATION

Albumin Tannate Combinations (ATC A07XA51): Toxicology and Lactation Monograph

A07XA51 designates albumin tannate combinations, classified among other antidiarrhoeal medicines. Their lactation assessment cannot be made solely from the ATC code: the safety profile depends critically on the exact co-formulated active ingredient(s), their doses, systemic absorption, and the health status of the breastfed infant.atcddd.fhi+1

ATC class and general pharmacology

ATC code: A07XA51
Designation: Albumin tannate, combinations
ATC group: A07XA — Other antidiarrhoeals
Therapeutic area: Antidiarrhoeal therapy

Albumin tannate is a complex formed from tannic acid and albumin or proteinaceous material. It has traditionally been used as a local gastrointestinal astringent. Its intended action is predominantly intraluminal: interaction with proteins at the intestinal mucosal surface may produce a protective, astringent effect and may reduce excessive intestinal secretion.

Unlike antimotility agents such as loperamide, albumin tannate is not primarily intended to suppress intestinal peristalsis. It belongs to the “other antidiarrhoeals” ATC subgroup, which includes agents with heterogeneous mechanisms. The A07XA51 designation specifically indicates that albumin tannate is present with one or more additional active substances; the ATC category itself does not identify those ingredients.atcddd.fhi+1

The pharmacological rationale for albumin tannate is usually based on limited systemic availability. Tannins are high-molecular-weight polyphenolic compounds capable of binding proteins and other macromolecules. In the gastrointestinal lumen, this property may contribute to local mucosal effects but may also modify the absorption of nutrients or concomitantly administered oral medicines.

Toxicological profile

The toxicological profile of albumin tannate is primarily determined by its local gastrointestinal activity and by the toxicology of its companion ingredients. When used at therapeutic doses for a short duration, albumin tannate itself is generally expected to have low systemic toxicity because meaningful systemic absorption is presumed to be limited. However, this premise should not be treated as proof of absence of systemic exposure, especially when intestinal permeability is altered by inflammation, infection, or severe diarrhoeal illness.

Potential adverse effects of tannin-containing gastrointestinal preparations include:

• Nausea, abdominal discomfort, constipation, or altered stool characteristics.
• Reduced absorption of orally administered medicines through adsorption, chelation, precipitation, or complex formation.
• Reduced absorption of certain nutrients when products are used repeatedly or for prolonged periods.
• Hypersensitivity reactions, although uncommon.
• Theoretical concern about excessive tannin exposure in infants and young children, particularly if formulations are incorrectly dosed or used for extended periods.

Astringent antidiarrhoeals do not address dehydration, electrolyte loss, invasive bacterial infection, inflammatory bowel disease, foodborne toxin exposure, or other causes of acute diarrhoea. Oral rehydration remains fundamental. Medical review is necessary when diarrhoea is accompanied by fever, blood or mucus in stool, marked abdominal pain, persistent vomiting, signs of dehydration, poor general condition, or prolonged symptoms.

For a combination product, toxicological risk may be substantially altered by an additional active component. A product that contains an antimicrobial, antisecretory agent, adsorbent, probiotic, salicylate, anticholinergic substance, opioid-related antimotility medicine, or another pharmacologically active ingredient cannot be classified on the basis of albumin tannate alone.

Lactation pharmacology and infant exposure

No robust human lactation studies were identified for albumin tannate combinations as a therapeutic group. Specifically, published data are insufficient to define albumin tannate concentrations in human milk, milk-to-plasma ratios, relative infant dose, breastfed infant serum concentrations, or systematically collected infant outcomes. Therefore, quantitative assessment of infant exposure is not possible from the A07XA51 classification alone.

For albumin tannate alone, clinically important passage into milk is theoretically unlikely if systemic maternal absorption is minimal. The compound’s local gastrointestinal action and expected low bioavailability support this inference. In addition, even if trace tannin-related material were present in milk, the amount reaching the infant would be expected to be limited by maternal absorption and subsequent transfer. This is a pharmacological inference, not direct clinical evidence.

The combination ingredient is the decisive exposure variable. A07XA51 products may differ between countries and manufacturers; the following information must be established before a lactation recommendation is issued:

• Full qualitative and quantitative composition.
• Pharmaceutical form, dose, dosing interval, and intended treatment duration.
• Maternal renal, hepatic, gastrointestinal, and allergic history.
• Age, gestational maturity, clinical condition, and feeding status of the infant.
• Presence of other medicines used by either mother or infant.

Theoretical infant effects, if clinically meaningful exposure occurs, include changes in stool frequency or consistency, constipation, feeding difficulty, vomiting, gastrointestinal discomfort, cutaneous hypersensitivity, or effects specific to the co-formulated ingredient. Infants who are premature, neonates, medically unstable, dehydrated, growth-restricted, or affected by renal or gastrointestinal disease should be considered higher-risk recipients.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: Indeterminate for the ATC combination category; assess the exact formulation. Albumin tannate alone is likely to present low systemic-transfer potential, but the combination component may change the risk materially.

Breastfeeding should not routinely be interrupted solely because a lactating person requires short-term management of uncomplicated diarrhoea. However, A07XA51 should not be considered a single, uniformly lactation-compatible drug. A safe recommendation requires identification of every active ingredient in the marketed product. This reflects the general principle that infant exposure through milk depends on maternal drug concentration, transfer into milk, infant oral absorption, and infant clearance.psychopharmacologyinstitute

Clinical recommendations:

• Obtain the full product name and list of active ingredients before prescribing, dispensing, or advising on A07XA51 during lactation.
• Prioritize oral rehydration therapy and evaluate the cause and severity of maternal diarrhoea; pharmacotherapy is adjunctive rather than a replacement for rehydration.
• If the product contains only albumin tannate and other low-absorption local gastrointestinal components, short-term use is likely to be compatible with breastfeeding in a healthy mother of a healthy term infant, although direct lactation data are lacking.
• If the combination contains a systemically absorbed medicine, assess that ingredient independently using lactation-specific evidence before use.
• Use the lowest effective dose for the shortest clinically necessary period.
• Avoid prolonged or repeated use without diagnostic reassessment because of possible interference with nutrient or medicine absorption and because persistent diarrhoea requires evaluation.
• Monitor the breastfed infant for constipation, diarrhoea, feeding changes, vomiting, rash, unusual irritability, or poor weight gain.
• Use extra caution or seek specialist lactation/pharmacology advice when the infant is preterm, younger than 2 months, medically complex, dehydrated, or has impaired renal or gastrointestinal function.

Suggested ToxiLact-style classification: Tier 3 — Insufficient formulation-specific lactation data; conditional use only after identification and assessment of all components. For a verified formulation containing only minimally absorbed local agents, the individual assessment may reasonably be downgraded to a lower-risk tier. Conversely, the presence of a systemically active co-ingredient may warrant a higher-risk classification or use of an alternative.